Chugai Pharmaceutical Co Ltd (4519.T)
17 Nov 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|70||2012||Chairman of the Board, Chief Executive Officer, Representative Director|
|64||2012||President, Chief Operating Officer, Representative Director|
|59||2012||Vice Chairman of the Board, Representative Director|
|63||2016||Chief Financial Officer, Senior Executive Officer, Senior Manager of Finance, Director|
|2016||Executive Officer, Director of Finance & Accounting, Senior Manager of IT|
- BRIEF-R&I affirms Chugai Pharmaceutical's rating at "AA-" and says stable outlook -R&I
- Roche's Chugai transfers rights of 13 Long-Term Listed Products to Taiyo
- BRIEF-Marketing and manufacturing right transfer of 13 long-term listed products from Chugai Pharmaceutical to Taiyo Pharma
- BRIEF-Chugai Pharma considering selling production rights of some medications to Taiyo - Nikkei
- BRIEF-Chugai Pharmaceutical says lawsuit on patent infringement concerning Herceptin® injection and petition for provisional disposition order